OpenDNA is developing an AI platform that combines clinical and genomic data analysis for polygenic diseases. The platform allows healthcare providers and payers to easily apply genomic precision medicine and population genomics approaches. Its prediction models help identify high risk patients and their key (or targeted) prevention strategies. The company has already implemented its AI solutions for cardiometabolic syndrome, and in the future means to apply the technology to other complex polygenic disease states, such as cancer; chronic kidney failure; and autoimmune, neurological, and musculoskeletal diseases.